echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Nanjing is sunny "Mirabelon slow release film" newspaper listed for bladder over-activity.

    Nanjing is sunny "Mirabelon slow release film" newspaper listed for bladder over-activity.

    • Last Update: 2020-09-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 24, Nanjing Zhengda Tianqing 4 class of generic drug "Mirabelon slow release tablets" submitted a listing application and was accepted by CDE, for the second domestic newspaper listing.
    , there is no similar varieties of generic drugs approved in China.
    Mirabelon is the first approved beta-3-subject excitant for bladder hyperactive disorder (OAB) to selectively relax the bladder by acting on beta epinephrine (beta-ARs) to force urine muscles and promote urine storage, thereby increasing bladder capacity and prolonging urination intervals without affecting bladder emptying.
    the drug was first developed by Astellas and first listed in Japan in 2011, followed by the United States, the United Kingdom, Europe and Canada, and was approved by NMPA in September 2017 for domestic listing under the name Bettanli ®.
    public data show global sales of $1.35 billion in 2018 and terminal sales of 140,000 yuan for public medical institutions in China in the same year after listing in China at the end of May 2018.
    the Insight database, Mirabelon has only been approved for the domestic market, and no generic drugs have been approved.
    With the exception of Nanjing Zhengda Tianqing, only one company submitted for listing was listed in October 2019 and was approved for priority review in April 2020, one year before the patent expired.
    addition, there are five companies undergoing BE trials, namely Ruiyang Pharmaceuticals, Jiangsu Huayang Pharmaceuticals, Shenzhen Wanle Pharmaceuticals, Shanxiang Pharmaceuticals, Sichuan Guowei Pharmaceuticals.
    from: Insight Database ()
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.